You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和鉑醫藥-B(02142.HK)公佈年度業績:總收入同比增長119.9%,首次實現年度財務盈利
格隆匯 03-29 09:31

格隆匯3月29日丨3月28日晚間,和鉑醫藥-B(02142.HK)公佈2023年度業績。截止2023年12月31日,和鉑醫藥全年總盈利2276萬美元,這也是公司首次實現年度財務盈利。

報吿期內,總收入達8950萬美元,同比增長119.9%(2022年總收入為4066萬美元),公司的收入構成主要包括產品授權、研究服務和技術授權,總收入的增長主要得益於與輝瑞、Cullinan Oncology和科倫博泰的授權合作。

報吿期內,全年研發總投入4508萬美元,同比下降66.6%(2022年研發總投入為1.35億美元),研發費用的降低主要受兩個因素的綜合影響,一是對自有臨牀項目以及處於早期發現和臨牀前階段項目的優化投資,二是高效實施成本控制的措施。

報吿期內,全年管理費用共計1950萬美元,同比下降28.6%(2022年管理費總計2727萬美元)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account